News from kahr medical A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

May 31, 2023, 07:30 ET KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors

KAHR, a clinical-stage biotech company developing DSP107, a novel, bi-specific CD47x4-1BB targeting immunotherapy that activates innate and adaptive...

Nov 17, 2022, 04:00 ET Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR's Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma

KAHR, a clinical-stage biotech company developing a novel, bi-specific CD47x4-1BB targeting immunotherapy that activates innate and adaptive immunity ...

Jul 11, 2022, 07:00 ET KAHR Announces Appointment of Jennifer Minai-Azary to its Board of Directors

KAHR, a clinical-stage cancer immunotherapy company developing novel bi-functional fusion proteins, today announced the appointment of Jennifer...

Mar 15, 2022, 07:00 ET KAHR Announces Publication of Preclinical Data Indicating Monotherapy and Combination Treatment Potential of its Investigational Anti-CD47 Fusion Protein

KAHR, a clinical stage cancer immunotherapy company developing novel dual-targeting protein therapeutics, today announced publication of preclinical...

Feb 17, 2022, 07:00 ET KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers

KAHR, a clinical stage oncology company developing novel dual-targeting fusion protein therapeutics, and Cancer Focus Fund, LP, a unique investment...

Sep 02, 2021, 07:00 ET KAHR Announces FDA Clearance of IND Application for Phase 1b Trial of its Lead Anti-CD47 Candidate in Blood Cancers

KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced that the U.S. Food and Drug...

Jun 16, 2021, 06:30 ET KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline

KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced the first closing of an investment ...

Apr 01, 2021, 07:35 ET KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy

KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, announced today that it has entered into a...

Nov 12, 2020, 06:45 ET KAHR Announces First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of Solid Tumors

KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced dosing of the first patient in its ...

Oct 15, 2020, 08:36 ET KAHR Announces Addition of Prof. Hagop M. Kantarjian to Its Clinical Advisory Board

KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced that Prof. Hagop M. Kantarjian,...

Oct 12, 2020, 06:30 ET KAHR Announces Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting

KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced that an abstract reporting...

Oct 05, 2020, 03:00 ET KAHR Announces Two Key Appointments to Strengthen Leadership Team

KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced that Aron Knickerbocker has been...

Aug 13, 2020, 07:30 ET KAHR Medical to Present at Oppenheimer's Private Life Sciences Company Call Series

KAHR Medical today announced the company's participation in Oppenheimer's Private Life Sciences Company Call Series taking place virtually August...

Aug 12, 2020, 03:00 ET KAHR Medical Announces FDA Clearance of IND Application for DSP107, anti-CD47 Candidate for the Treatment of Solid Tumors

KAHR Medical, a cancer immunotherapy company developing novel bi-functional fusion proteins, announced today that the U.S. Food and Drug...

Feb 25, 2020, 19:30 ET KAHR Medical Raises $18 Million in Private Funding Round

Feb 25, 2020, 04:31 ET KAHR Medical Raises $18 Million in Private Funding Round

KAHR Medical Ltd., a biopharmaceutical company developing a novel drug platform based on bi-functional, immunotherapeutic fusion proteins known as...

Sep 09, 2019, 07:10 ET KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients

KAHR Medical, a biopharmaceutical company developing a novel drug platform based on bi-functional, immunotherapeutic fusion proteins known as DSP...